HONG KONG, July 28, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the National Medical Products Administration (NMPA) has accepted the supplementary New Drug Application (sNDA) for ivonescimab (PD-1/VEGF bispecific antibody) in...
Hence then, the article about nmpa accepts snda for ivonescimab in combination with chemotherapy as first line treatment for advanced squamous non small cell lung cancer was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( NMPA Accepts sNDA for Ivonescimab in Combination with Chemotherapy as First-Line Treatment for Advanced Squamous Non-Small Cell Lung Cancer )
Also on site :
- Nicotine pouch tax increase aims to protect kids, but producers and lawmakers fear impact on smokers trying to quit
- Authorities Searching for Suspect After Woman Stabbed to Death in Hillsborough
- Coalition Of Public Interest Groups Call For State Attorneys General To Challenge Paramount-Warner Bros. Discovery Merger